Glaxosmithkline Pharmaceuticals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kntg8nsfr7xcc0ls2knv1gpw.pdf

Key Takeaways


Top-Line Performance & Underlying Growth

Bhushan Akshikar: "I think our priorities remain firmly anchored around the three priorities that we have set for ourselves as a global biopharma corporation. The first one being relentless pursuit of the top-line growth. ... And then bolting on the second priority, which is really accelerating all the new launches. We have an extensive array of launches coming up in the next 24 to 36 months. ... And third, anything that comes in the way of these two priorities, you know, hacking those inefficiencies and simplifying the ways of working."

Innovation & Specialty Portfolio

Ronojit Biswas: "We're very excited about, our launch of Blenrep, which is going to happen in the December quarter. This will take us into this adds to our oncology portfolio. It takes us into the hemato-oncology space with, you know, with an ADC in multiple myeloma."

Vaccines


Margins & Cost Structure

Ronojit Biswas: "What we are also seeing is that procurement prices of, several key input materials, APIs, packaging material, these are all oil price, these are all kind of significantly oil price linked. So, we expect the geopolitical situation to have an impact for a few quarters until the oil prices stabilize."

Strategic Ambition: The 2x Plan

Management: "It's not about an either-or, it's an and strategy for us in India."

Regulatory & Pricing Environment


Guidance & Commitments

CommitmentSpecificsTimeline
Blenrep launchEnter hemato-oncology space with ADC in multiple myelomaQ3 FY27 (December quarter)
Hibsago India launchApply for Indian regulatory approvals for chronic hepatitis B functional cureComing 12 months
Input cost pressureOil-linked procurement cost headwinds to persistA few quarters, until oil prices stabilize
Double the businessReach ~INR 8,000 crores revenueBy 2031
Blended growth rate12–13% blended growth over the next five yearsFive-year period
Established products growthHigh single-digit growth for Gen Meds and paediatric vaccinesNext 3–5 years
Specialty sales modelReplicate nimble 30–50 person team model for each new specialty unitComing 12 months
H2 growthDeliver double-digit growthSecond half of FY27
Margin profileMaintain current profitability levels while prioritizing top-line growthOngoing
Oncology pricing impactNo impact from trade margin rationalization on existing or near-term launchesComing two quarters of FY27

Key Metrics

MetricQ2 FY27
Revenue₹1,180 cr, +21% YoY; highest quarterly sales recorded
Underlying revenue growth12–13%, excluding low base effect from prior-year CMO fire and GST 2.0
EBITDA₹400 cr, +20% YoY
EBITDA margin34%, maintained; gross margin erosion of ~120 bps offset by ~1 ppt improvement in spend ratio
Underlying EBITDA growth~13%, stripping tailwinds
Profit after tax+33% YoY; includes one-off income tax refund interest of ~₹42 cr
Underlying PAT growth~21%, in line with sales growth, excluding one-off
Earnings per share₹19.76, +32% YoY
Cash on balance sheet₹2,200 cr, zero debt
Cash conversion ratio98%
H1 FY27 revenue growth18%
H1 FY27 EBITDA growth18%
H1 FY27 PAT growth29%
Innovation portfolio revenue share7% of overall revenues, up from ~3% in Q2 FY26
Innovation portfolio growth contribution~25% of overall growth
Shingrix sales growthDoubled vs Q2 FY26
Oncology patient impact~300 patients treated quarterly with Zejula and Jemperli
General medicines volume growth5–7%, mid to high single-digit
Calpol underlying growth30–35% for Q2; Evolution Index ahead of 112%
Gross margin erosion~120 bps, driven by rupee appreciation and oil-linked input cost inflation
Industry market growth (IQVIA)~14–14.5% overall; chronic +17%, acute +13%
Anti-infectives segment growth7.1%, roughly half the industry rate
Revenue aspiration~₹8,000 cr by 2031, roughly double FY26 levels; ~3/5 from established portfolio, ~2/5 from new launches
Blended growth rate aspiration12–13% over next five years
Oncology team size~50 people across solid tumors and hematological malignancies
Clinical trials in India30+ pivotal Phase 3A/3B global trials, up from 10–12 four years ago
Big brands in portfolio11–12 assets deemed big by IQVIA (>₹100–150 cr); 4–5 in top 20
Specialty brand potential₹300–400 cr individually per brand